Alternative cancer treatment could replace chemo and surgery, study suggests
New cancer research pioneered by Memorial Sloan Kettering points to a strong alternative to chemotherapy, surgery and radiation for some forms of cancer.
Nearly 80% of patients who suffered from a variety of cancer types were successfully treated with only immunotherapy, according to a new study published in The New England Journal of Medicine.
The immunotherapy protocol successfully treated 100% of rectal cancer patients involved in the trial.
"My husband, Tommy, and I were preparing for the worst," recalled Maureen Sideris, who was diagnosed with gastroesophageal junction cancer in 2022 and subsequently became a participant in the trial.
"After being treated with only immunotherapy, I had no evidence of cancer and didn't have to undergo surgery, chemo or radiation," she said in an MSK press release. "I felt like I won the lottery!"
Dr. Andrea Cercek, a gastrointestinal oncologist, oversaw the research along with fellow gastrointestinal oncologist Dr. Luiz Diaz.
The pair sought to develop this approach in part due to the negative impacts of traditional treatment, according to the release.
"Using the standard-of-care treatment of surgery, radiation and chemotherapy to treat rectal cancer is effective," Cercek said.
"But the treatments can leave people infertile and severely affect bowel, urinary and sexual functions, as well as other aspects of daily life."
"After being treated with only immunotherapy, I had no evidence of cancer and didn't have to undergo surgery, chemo or radiation."
Participants in the trial were all patients with tumors ranging from stage 1 to stage 3, meaning the tumors had not yet spread, the release indicated.
The tumors also had a genetic mutation called mismatch repair-deficient (MMRd), which makes them particularly vulnerable to a type of immunotherapy called "checkpoint inhibitors."
This therapy "unmasks" tumor cells, MSK stated, making it easier for the patient's own immune system to recognize and kill cancer cells.
The first clinical trial testing the therapy started with only 18 patients, all of whom had rectal cancer.
"We knew there was a broad range of cancer types that had this same MMRd genetic mutation," Cercek said. "We hoped this approach could help people facing these other cancers, too."
In the expanded trial, which contained 103 patients, there were 49 rectal cancer patients and 54 patients with other types of cancer. Participants received checkpoint inhibitor infusions intravenously over the course of six months, per the release.
In all 49 rectal cancer patients, there was no evidence of cancer after immunotherapy.
Of the 54 patients with other cancers, 35 saw all signs of cancer disappear after therapy, according to a variety of tests performed for the study.
"This is a very significant response, and the results were even better than we had hoped," said Cercek. "We found that some cancer types responded extremely well to the immunotherapy, including colon and stomach cancer."
In the 20% of non-rectal cancer patients who still needed surgery post-therapy, researchers saw that the immunotherapy often shrunk the tumor and even lowered the stage classifications of some of the tumors, according to Cercek.
Timothy Yap, Ph.D., a medical oncologist at the University of Texas MD Anderson Cancer Center, agrees that the immunotherapy treatment's effectiveness for multiple kinds of cancer is "exciting."
"We are always seeking to improve treatment strategies for cancer patients through innovative clinical trials, and this is no exception," Yap, who was not involved in the study, told Fox Digital.
"Responding patients may avoid the need for surgery, chemotherapy and radiation therapy, and benefit by improving their quality of life," he said.
"This is a very significant response, and the results were even better than we had hoped."
Based on the results of the original trial with rectal patients, the immunotherapy-only approach has been incorporated into the treatment guidelines of the National Comprehensive Cancer Network, which is the doctor's group that sets cancer treatments in the U.S., the release stated.
For more Health articles, visit www.foxnews.com/health
Some of the original participants of the 2022 trial are still cancer-free today, multiple years after the initial treatment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
US Bursitis and BMI Predict Joint Issues in Psoriasis
In patients with mild psoriasis and no initial musculoskeletal signs, ultrasound bursitis at entheses was associated with the development of inflammatory symptoms suggestive of psoriatic arthritis (PsA), and those who developed musculoskeletal symptoms had higher BMI and fatigue scores and had a higher risk for transition to PsA. METHODOLOGY: This prospective multicentre study included 78 patients with mild psoriasis without musculoskeletal symptoms who were not on systemic treatment; 82% of them had mild disease and 39.7% presented with onychopathy. Researchers performed ultrasound evaluation of 40 joints and 10 entheses bilaterally at baseline and during follow-up; these were assessed for synovial hypertrophy, power Doppler signal, and entheseal changes including bursitis. Study outcomes were the diagnosis of PsA and new-onset musculoskeletal symptoms. The median follow-up duration was 76.6 months. TAKEAWAY: Among 60 patients who completed the study, 6.6% developed PsA over a mean of 20.2 months according to the CASPAR criteria, corresponding to the annual incidence of approximately 1%. Overall, 56.6% of patients developed musculoskeletal symptoms and had significantly higher BMI ( P = .013) and abdominal circumference ( P = .022) at baseline. = .013) and abdominal circumference ( = .022) at baseline. These patients also scored higher on pain (2.14 vs 0.91; P = .047) and fatigue (3.25 vs 1.21; P = .011) components of the baseline Psoriatic Arthritis Impact of Disease questionnaire than those not developed musculoskeletal symptoms. = .047) and fatigue (3.25 vs 1.21; = .011) components of the baseline Psoriatic Arthritis Impact of Disease questionnaire than those not developed musculoskeletal symptoms. Ultrasound bursitis at entheses was present in 80% of patients who developed inflammatory arthralgia suggestive of PsA ( P = .049). = .049). The total joint ultrasound score at baseline was significantly higher in patients who developed musculoskeletal symptoms ( P = .037). IN PRACTICE: "Around half of the patients with PsO [psoriasis] developed MSK [musculoskeletal] symptoms during the follow-up and they had significantly higher BMI, more joint US [ultrasound] findings and scored higher in pain and fatigue scales at baseline PsAID [Psoriatic Arthritis Impact of Disease] questionnaire, defining a subgroup with potentially higher risk to develop PsA. On the other hand, US bursitis at enthesis was related to the onset of MSK symptoms suggestive of PsA," the authors wrote. SOURCE: This study was led by Ana Belén Azuaga, Hospital Clinic, Barcelona, Spain. It was published online on June 04, 2025, in Rheumatology . LIMITATIONS: The sample size was relatively small, potentially underestimating the incidence of PsA in patients with psoriasis. The exclusion of patients with musculoskeletal symptoms and those on systemic therapy likely excluded individuals with a higher risk of developing PsA. Additionally, a significant proportion of patients initiated disease-modifying antirheumatic drug therapy during the study, including biologics, which could have affected the development of PsA symptoms. DISCLOSURES: This study was supported by research grants from Pfizer and Novartis. Additional support came from the Innovative Medicines Initiative 2 Joint Undertaking. The authors declared having no conflicts of interest.
Yahoo
2 days ago
- Yahoo
Fully insured medical claims analysis shows significant cost savings and 2.4x ROI for Hinge Health populations
Methodology validated by leading global benefits consultant SAN FRANCISCO, June 10, 2025--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced results from a medical claims analysis revealing an average $2,343 savings per member per year on care for chronic musculoskeletal (MSK) conditions and a 2.4x return on investment (ROI) for fully insured health plan members using its digital MSK platform. The methodology of the medical claims analysis of 4,788 health plan members was validated by Gallagher, a leading global insurance brokerage, risk management, and consulting firm. MSK costs remain one of the top drivers of health costs, placing increasing pressure on benefits leaders to ensure programs deliver value and cost-efficiency. The medical claims analysis examined the impact of Hinge Health on medical care costs and utilization among participants enrolled in fully insured health plans. The study found meaningful cost savings from reduced utilization across a spectrum of healthcare services, including injections and physical or occupational therapy, with the majority of claims reductions (44%) coming from avoided surgeries. "Employers today face tremendous pressure to contain costs without sacrificing the quality of employee benefits," said Jim Pursley, President, Hinge Health. "This analysis proves that health plans can deliver better health outcomes and an outstanding member experience with Hinge Health, while driving down healthcare spend." The analysis leveraged a claims database that represented more than 100 million commercially insured lives from January 1, 2017 to September 30, 2023. To estimate savings, the study compared medical cost and utilization between Hinge Health participants and a matched control group between a baseline year and the 12 months after Hinge Health members started care. This new analysis builds upon previous cost analysis studies that demonstrate the cost-savings that Hinge Health provides. Hinge Health's digital MSK platform has consistently shown a financial benefit of more than 2x ROI across industries and participant demographics through multiple third-party validations, including a multi-employer study and Medicare population evaluation. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California. View source version on Contacts media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 days ago
- Business Wire
Fully insured medical claims analysis shows significant cost savings and 2.4x ROI for Hinge Health populations
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced results from a medical claims analysis revealing an average $2,343 savings per member per year on care for chronic musculoskeletal (MSK) conditions and a 2.4x return on investment (ROI) for fully insured health plan members using its digital MSK platform. The methodology of the medical claims analysis of 4,788 health plan members was validated by Gallagher, a leading global insurance brokerage, risk management, and consulting firm. MSK costs remain one of the top drivers of health costs, placing increasing pressure on benefits leaders to ensure programs deliver value and cost-efficiency. The medical claims analysis examined the impact of Hinge Health on medical care costs and utilization among participants enrolled in fully insured health plans. The study found meaningful cost savings from reduced utilization across a spectrum of healthcare services, including injections and physical or occupational therapy, with the majority of claims reductions (44%) coming from avoided surgeries. 'Employers today face tremendous pressure to contain costs without sacrificing the quality of employee benefits,' said Jim Pursley, President, Hinge Health. 'This analysis proves that health plans can deliver better health outcomes and an outstanding member experience with Hinge Health, while driving down healthcare spend.' The analysis leveraged a claims database that represented more than 100 million commercially insured lives from January 1, 2017 to September 30, 2023. To estimate savings, the study compared medical cost and utilization between Hinge Health participants and a matched control group between a baseline year and the 12 months after Hinge Health members started care. This new analysis builds upon previous cost analysis studies that demonstrate the cost-savings that Hinge Health provides. Hinge Health's digital MSK platform has consistently shown a financial benefit of more than 2x ROI across industries and participant demographics through multiple third-party validations, including a multi-employer study and Medicare population evaluation. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California.
